Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder / Benjamin L. Handen en Journal of the American Academy of Child & Adolescent Psychiatry, Año 2015 - Vol.54 - No.11 (Noviembre)

Público ISBD [artículo]  inJournal of the American Academy of Child & Adolescent Psychiatry > Año 2015 - Vol.54 - No.11 (Noviembre) . - pp. 905–915 Título : Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder Tipo de documento: texto impreso Autores: Benjamin L. Handen, Autor ; Michael G. Aman, Autor ; L. Eugene Arnold, Autor Fecha de publicación: 2020 Artículo en la página: pp. 905–915 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Atomoxetina, Entrenamiento para padres, TDAH, Trastorno del espectro autista, Ensayo clínico Resumen: Impairments associated with attention-deficit/hyperactivity disorder (ADHD) and noncompliance are prevalent in children with autism spectrum disorder (ASD). However, ADHD response to stimulants is well below rates in typically developing children, with frequent side effects. Link: ./index.php?lvl=notice_display&id=22579 [artículo] Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder [texto impreso] / Benjamin L. Handen, Autor ; Michael G. Aman, Autor ; L. Eugene Arnold, Autor . - 2020 . - pp. 905–915. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of the American Academy of Child & Adolescent Psychiatry > Año 2015 - Vol.54 - No.11 (Noviembre) . - pp. 905–915 Palabras clave: Atomoxetina, Entrenamiento para padres, TDAH, Trastorno del espectro autista, Ensayo clínico Resumen: Impairments associated with attention-deficit/hyperactivity disorder (ADHD) and noncompliance are prevalent in children with autism spectrum disorder (ASD). However, ADHD response to stimulants is well below rates in typically developing children, with frequent side effects. Link: ./index.php?lvl=notice_display&id=22579

A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder / Benjamin L. Handen en Journal of the American Academy of Child & Adolescent Psychiatry, Año 2017 - Vol. 56 - No.10 ([18/12/2017])

Público ISBD [artículo]  inJournal of the American Academy of Child & Adolescent Psychiatry > Año 2017 - Vol. 56 - No.10 [18/12/2017] . - pp. 849-856 Título : A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder : Open-Label Extension Tipo de documento: texto impreso Autores: Benjamin L. Handen, Autor ; Evdokia Anagnostou, Autor ; Michael G. Aman, Autor Fecha de publicación: 2017 Artículo en la página: pp. 849-856 Idioma : Inglés (eng) Palabras clave: Metformina, Trastorno del Espectro Autista, Aumento de Peso, Medicación Antipsicótica. Resumen: A previous study reported on a 16-week placebo-controlled, randomized clinical trial (RCT) of metformin for weight stabilization in 61 children and adolescents 6 to 17 years old with autism spectrum disorder who were prescribed atypical antipsychotics. Link: ./index.php?lvl=notice_display&id=9717 [artículo] A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder : Open-Label Extension [texto impreso] / Benjamin L. Handen, Autor ; Evdokia Anagnostou, Autor ; Michael G. Aman, Autor . - 2017 . - pp. 849-856. Idioma : Inglés (eng) in Journal of the American Academy of Child & Adolescent Psychiatry > Año 2017 - Vol. 56 - No.10 [18/12/2017] . - pp. 849-856 Palabras clave: Metformina, Trastorno del Espectro Autista, Aumento de Peso, Medicación Antipsicótica. Resumen: A previous study reported on a 16-week placebo-controlled, randomized clinical trial (RCT) of metformin for weight stabilization in 61 children and adolescents 6 to 17 years old with autism spectrum disorder who were prescribed atypical antipsychotics. Link: ./index.php?lvl=notice_display&id=9717

---

1 (1 - 2 / 2)